Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy
Mahidol University
140 participants
Jan 10, 2025
INTERVENTIONAL
Conditions
Summary
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06850454